Inflammopharmacology SCIE

國際簡稱：INFLAMMOPHARMACOLOGY 參考譯名：炎癥藥理學(xué)

主要研究方向：IMMUNOLOGYTOXICOLOGY-TOXICOLOGY 非預(yù)警期刊審稿周期：

《炎癥藥理學(xué)》(Inflammopharmacology)是一本由Springer International Publishing出版的以IMMUNOLOGYTOXICOLOGY-TOXICOLOGY為研究特色的國際期刊，發(fā)表該領(lǐng)域相關(guān)的原創(chuàng)研究文章、評論文章和綜述文章，及時報道該領(lǐng)域相關(guān)理論、實(shí)踐和應(yīng)用學(xué)科的最新發(fā)現(xiàn)，旨在促進(jìn)該學(xué)科領(lǐng)域科學(xué)信息的快速交流。該期刊是一本未開放期刊，近三年沒有被列入預(yù)警名單。該期刊享有很高的科學(xué)聲譽(yù)，影響因子不斷增加，發(fā)行量也同樣高。

2區(qū) 中科院分區(qū)
Q1 JCR分區(qū)
263 年發(fā)文量
4.6 IF影響因子
未開放 是否OA
45 H-index
1991 創(chuàng)刊年份
6 issues per year 出版周期
English 出版語言

Inflammopharmacology is the official publication of the Gastrointestinal Section of the International Union of Basic and Clinical Pharmacology (IUPHAR) and the Hungarian Experimental and Clinical Pharmacology Society (HECPS). Inflammopharmacology publishes papers on all aspects of inflammation and its pharmacological control emphasizing comparisons of (a) different inflammatory states, and (b) the actions, therapeutic efficacy and safety of drugs employed in the treatment of inflammatory conditions. The comparative aspects of the types of inflammatory conditions include gastrointestinal disease (e.g. ulcerative colitis, Crohn's disease), parasitic diseases, toxicological manifestations of the effects of drugs and environmental agents, arthritic conditions, and inflammatory effects of injury or aging on skeletal muscle. The journal has seven main interest areas:

-Drug-Disease Interactions - Conditional Pharmacology - i.e. where the condition (disease or stress state) influences the therapeutic response and side (adverse) effects from anti-inflammatory drugs. Mechanisms of drug-disease and drug disease interactions and the role of different stress states

-Rheumatology - particular emphasis on methods of measurement of clinical response effects of new agents, adverse effects from anti-rheumatic drugs

-Gastroenterology - with particular emphasis on animal and human models, mechanisms of mucosal inflammation and ulceration and effects of novel and established anti-ulcer, anti-inflammatory agents, or antiparasitic agents

-Neuro-Inflammation and Pain - model systems, pharmacology of new analgesic agents and mechanisms of neuro-inflammation and pain

-Novel drugs, natural products and nutraceuticals - and their effects on inflammatory processes, especially where there are indications of novel modes action compared with conventional drugs e.g. NSAIDs

-Muscle-immune interactions during inflammation [...]

[ 查看全部 ]

投稿咨詢加急咨詢

Inflammopharmacology期刊信息

ISSN：0925-4692
出版語言：English
是否OA：未開放
E-ISSN：1568-5608
出版地區(qū)：NETHERLANDS
是否預(yù)警：否
出版商：Springer International Publishing
出版周期：6 issues per year
創(chuàng)刊時間：1991
開源占比：0.128
Gold OA文章占比：20.93%
OA被引用占比：0.0576...
出版國人文章占比：0.15
出版撤稿占比：0
研究類文章占比：65.78%

Inflammopharmacology CiteScore評價數(shù)據(jù)（2024年最新版）

CiteScore

SJR

SNIP

CiteScore 指數(shù)

0.952

1.006

學(xué)科類別	分區(qū)	排名	百分位
大類：Medicine 小類：Pharmacology (medical)	Q1	37 / 272	86%
大類：Medicine 小類：Pharmacology	Q1	70 / 313	77%
大類：Medicine 小類：Immunology	Q2	80 / 236	66%

名詞解釋：CiteScore 是衡量期刊所發(fā)表文獻(xiàn)的平均受引用次數(shù)，是在 Scopus 中衡量期刊影響力的另一個指標(biāo)。當(dāng)年CiteScore 的計(jì)算依據(jù)是期刊最近4年（含計(jì)算年度）的被引次數(shù)除以該期刊近四年發(fā)表的文獻(xiàn)數(shù)。例如，2022年的 CiteScore 計(jì)算方法為：2022年的 CiteScore =2019-2022年收到的對2019-2022年發(fā)表的文件的引用數(shù)量÷2019-2022年發(fā)布的文獻(xiàn)數(shù)量注：文獻(xiàn)類型包括：文章、評論、會議論文、書籍章節(jié)和數(shù)據(jù)論文。

Inflammopharmacology中科院評價數(shù)據(jù)

中科院 2023年12月升級版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	2區(qū)	TOXICOLOGY 毒理學(xué) IMMUNOLOGY 免疫學(xué)	1區(qū) 3區(qū)

中科院 2022年12月升級版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	2區(qū)	IMMUNOLOGY 免疫學(xué) TOXICOLOGY 毒理學(xué)	2區(qū) 2區(qū)

中科院 2021年12月舊的升級版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	3區(qū)	IMMUNOLOGY 免疫學(xué) TOXICOLOGY 毒理學(xué)	3區(qū) 3區(qū)

中科院 2021年12月基礎(chǔ)版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	3區(qū)	IMMUNOLOGY 免疫學(xué) TOXICOLOGY 毒理學(xué)	3區(qū) 2區(qū)

中科院 2021年12月升級版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	3區(qū)	IMMUNOLOGY 免疫學(xué) TOXICOLOGY 毒理學(xué)	3區(qū) 3區(qū)

中科院 2020年12月舊的升級版

Top期刊	綜述期刊	大類學(xué)科		小類學(xué)科
否	否	醫(yī)學(xué)	3區(qū)	IMMUNOLOGY 免疫學(xué) TOXICOLOGY 毒理學(xué)	3區(qū) 3區(qū)

Inflammopharmacology JCR評價數(shù)據(jù)（2023-2024年最新版）

按JIF指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：IMMUNOLOGY	SCIE	Q2	56 / 181	69.3%
學(xué)科：TOXICOLOGY	SCIE	Q1	17 / 106	84.4%

按JCI指標(biāo)學(xué)科分區(qū)	收錄子集	分區(qū)	排名	百分位
學(xué)科：IMMUNOLOGY	SCIE	Q1	37 / 181	79.83%
學(xué)科：TOXICOLOGY	SCIE	Q1	17 / 106	84.43%

Inflammopharmacology歷年數(shù)據(jù)統(tǒng)計(jì)

影響因子

中科院分區(qū)

Inflammopharmacology中國學(xué)者發(fā)文選摘

1、Diosmetin alleviates acute lung injury caused by lipopolysaccharide by targeting barrier function
Author: Xia, Jiying; Li, Junhong; Deng, Mengsheng; Yin, Fei; Liu, Jianhui; Wang, Jianmin

Journal: INFLAMMOPHARMACOLOGY. 2023; Vol. , Issue , pp. -. DOI: 10.1007/s10787-023-01228-7
2、Phytochemicals as potential target on thioredoxin-interacting protein (TXNIP) for the treatment of cardiovascular diseases
Author: Zhou, Peng; Ma, Yao-yao; Zhao, Xiao-ni; Hua, Fang

Journal: INFLAMMOPHARMACOLOGY. 2023; Vol. , Issue , pp. -. DOI: 10.1007/s10787-022-01130-8
3、Inhibition of STAT3 phosphorylation by colchicine regulates NLRP3 activation to alleviate sepsis-induced acute lung injury
Author: Liu, Yuanshui; Yang, Hang; Zhu, Fei; Ouyang, Yanhong; Pan, Pinhua

Journal: INFLAMMOPHARMACOLOGY. 2023; Vol. , Issue , pp. -. DOI: 10.1007/s10787-023-01199-9
4、Adalimumab combined with erythropoietin improves recovery from spinal cord injury by suppressing microglial M1 polarization-mediated neural inflammation and apoptosis
Author: Liu, Yanming; Zhang, Feiyue; Sun, Qi; Liang, Lichao

Journal: INFLAMMOPHARMACOLOGY. 2023; Vol. 31, Issue 2, pp. 887-897. DOI: 10.1007/s10787-022-01090-z
5、Suprabasin-derived polypeptides: SBSN(50-63) induces inflammatory response via TLR4-mediated mast cell activation
Author: Zhou, Tong; Du, Xueshan; Zhang, Lei; Zheng, Yi; Jia, Tao; Song, Xiangjin; Che, Delu; Geng, Songmei

Journal: INFLAMMOPHARMACOLOGY. 2023; Vol. , Issue , pp. -. DOI: 10.1007/s10787-023-01137-9
6、Synovial mesenchymal stem cell-derived exosomal microRNA-320c facilitates cartilage damage repair by targeting ADAM19-dependent Wnt signalling in osteoarthritis rats
Author: Kong, Ruina; Zhang, Ju; Ji, Lianmei; Yu, Yiyi; Gao, Jie; Zhao, Dongbao

Journal: INFLAMMOPHARMACOLOGY. 2023; Vol. 31, Issue 2, pp. 915-926. DOI: 10.1007/s10787-023-01142-y
7、A novel pharmacological mechanism of anti-cancer drugs that induce pyroptosis
Author: Guo, Haohao; Wang, Ziyang; Ma, Runsheng; Chen, Xin; Li, Hongqiang; Tang, Yifeng; Du, Gongbo; Zhang, Yifei; Yin, Detao

Journal: INFLAMMOPHARMACOLOGY. 2023; Vol. 31, Issue 2, pp. 745-754. DOI: 10.1007/s10787-023-01148-6
8、Daidzein attenuated paclitaxel-induced neuropathic pain via the down-regulation of TRPV1/P2Y and up-regulation of Nrf2/HO-1 signaling
Author: Zafar, Sana; Luo, Yong; Zhang, Li; Li, Chang Hu; Khan, Adnan; Khan, Muhammad Ibrar; Shah, Kifayatullah; Seo, Eun Kyoung; Wang, Feng; Khan, Salman

Journal: INFLAMMOPHARMACOLOGY. 2023; Vol. , Issue , pp. -. DOI: 10.1007/s10787-023-01225-w